Forbes contributors publish independent expert analyses and insights. Ge Bai is professor of accounting & health policy at Johns Hopkins. Biologic drugs, made from living organisms and usually taken ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

Biologic drugs are well established treatments for a wide range of disorders, and many of these medicines have become blockbuster products. But currently available biologics still have limitations, ...

Biologics are diverse, organic-based treatments like vaccines and gene therapy, requiring specific conditions for effectiveness. Unlike small molecules, biologics show batch variability and involve ...

Lowering the prices of prescription drugs has been high on United States President Donald Trump’s agenda since he took office in January. He has taken a number of steps, including striking deals with ...

Biosimilars provide cheaper alternatives to biologics, potentially reducing profitability for original drug makers. Long-lasting drug patents (up to 40.5 years) support sustained revenue for ...

Biologics, with their precision targeting, expand treatment options for a multitude of diseases - from cancer to autoimmune disorders. In 2023 alone, 10 antibody therapeutics received their first ...

The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars is a biologic medication that is highly similar to an ...